Clinic
Triad of Alabama LLC
Triad of Alabama LLC was paid $4.60M by Medicaid between Jan 2018 and Dec 2024, across 98 billing codes. Its largest line is 99284, emergency room visit (serious) — 25% of everything it billed.
33Billing provider infoTRIAD OF ALABAMA LLC
DOTHAN, AL 36305
DOTHAN, AL 36305
33aNPI1801830500assigned 06/15/2006
33bProvider typeLithotripsy Clinic/Center
28Total paid$4.60M
24GClaims213,545
24DCodes billed98
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 39,867 | $747K | |
| 2019 | 37,964 | $732K | |
| 2020 | 23,892 | $459K | |
| 2021 | 35,103 | $693K | |
| 2022 | 34,767 | $780K | |
| 2023 | 28,156 | $783K | |
| 2024incomplete | 13,796 | $401K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 25% | 19,818 | 17,762 | $1.15M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 28,552 | 26,051 | $1.03M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 3,652 | 3,347 | $730K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.5% | 6,225 | 5,732 | $252K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.7% | 24,021 | 21,168 | $169K |
| 80047 | 3.3% | 20,218 | 17,841 | $151K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.7% | 5,691 | 5,244 | $124K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 742 | 655 | $100K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.8% | 5,735 | 5,295 | $84K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 2,865 | 1,589 | $67K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.3% | 7,280 | 6,274 | $61K |
| 80076 | 1.2% | 10,132 | 9,068 | $55K |
86 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 724 | $51K |
| 83655 | 1.1% | 3,212 | $49K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,399 | $45K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,818 | $45K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,004 | $40K |
| 80053 | Comprehensive metabolic panel | <1% | 3,189 | $37K |
| 83735 | <1% | 5,188 | $29K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,679 | $26K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,329 | $23K |
| 84484 | <1% | 3,707 | $23K | |
| 84439 | <1% | 2,189 | $22K | |
| 81003 | <1% | 8,719 | $22K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,383 | $21K |
| 81025 | <1% | 6,345 | $19K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,542 | $14K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,097 | $14K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 508 | $12K |
| 83690 | <1% | 1,940 | $11K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 85 | $11K |
| 81001 | <1% | 3,078 | $10K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 324 | $9K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 96 | $7K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 271 | $5K |
| 82728 | <1% | 481 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 542 | $5K |
| 83550 | <1% | 426 | $5K | |
| 83516 | <1% | 195 | $4K | |
| 82784 | <1% | 296 | $4K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 13 | $4K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 419 | $4K |
| 93225 | <1% | 70 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,273 | $3K |
| 87807 | <1% | 233 | $3K | |
| 86364 | <1% | 184 | $2K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 85 | $2K |
| 86696 | <1% | 111 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 353 | $2K |
| 86695 | <1% | 111 | $2K | |
| 86592 | <1% | 372 | $2K | |
| 83540 | <1% | 269 | $2K | |
| 82962 | <1% | 346 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,438 | $2K |
| 59025 | Fetal non-stress test | <1% | 371 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 67 | $2K |
| 83880 | <1% | 116 | $2K | |
| 82977 | <1% | 219 | $1K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 256 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,309 | $1K |
| 74018 | <1% | 106 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 49 | $1K |
| 93226 | <1% | 13 | $889.80 | |
| 83605 | <1% | 111 | $784.70 | |
| 86140 | <1% | 351 | $695.55 | |
| 87186 | <1% | 155 | $657.15 | |
| 84702 | <1% | 53 | $644.79 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 21 | $632.30 |
| 80061 | Lipid panel | <1% | 39 | $593.30 |
| 87077 | <1% | 155 | $583.70 | |
| 87070 | <1% | 182 | $496.51 | |
| 82607 | <1% | 25 | $414.48 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,330 | $344.33 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 405 | $344.05 |
| 83001 | <1% | 12 | $290.88 | |
| 83002 | <1% | 12 | $288.72 | |
| 87040 | <1% | 32 | $247.95 | |
| 87205 | <1% | 179 | $220.17 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 65 | $163.38 |
| 72110 | <1% | 15 | $159.18 | |
| 73564 | <1% | 14 | $131.60 | |
| 82043 | <1% | 26 | $111.10 | |
| 73630 | <1% | 14 | $90.96 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 25 | $75.10 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 23 | $75.10 |
| 85610 | <1% | 14 | $69.24 | |
| 85730 | <1% | 14 | $35.04 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 42 | $27.54 |
| C1769 | Guide wire | 0% | 41 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 177 | $0.00 |
| 0240U | 0% | 28 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 31 | $0.00 |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 38 | $0.00 |
| 85027 | 0% | 19 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 71 | $0.00 |
| 99152 | 0% | 12 | $0.00 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 0% | 322 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.